IQVIA Holdings Inc.

IQVIA Holdings Inc.

IQV·NYSE

$182.05

-2.6%
HealthcareMedical - Diagnostics & Research

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

At a Glance

Live Snapshot
Market Cap$30.38B
EPS7.9100
P/E Ratio23.02
Earnings Date07/28/2026

iqv

Effect of Foreign Exchange Changes on Cash

Last Annual Value

79.00M

3-Year CAGR

45%

5-Year CAGR

21%

10-Year CAGR

14%

IQVIA Holdings Inc.

IQVIA Holdings Inc. Competitors Analysis of Effect of Foreign Exchange Changes on Cash

IQV · NYSE
CompanyEffect of Foreign Exchange Changes on Cash
CAGR 3Y
CAGR 5Y
CAGR 10Y
79.00M
N/AN/AN/A 
801.00K
N/A41.3%N/A
ILMN logo
Illumina, Inc.
NASDAQ:ILMN
11.00M
N/AN/AN/A
9.00M
21.6%24.6%N/A
HUM logo
Humana Inc.
NYSE:HUM
0.00
N/AN/AN/A
-3.00M
N/AN/AN/A
64.00M
N/AN/AN/A
RMD logo
ResMed Inc.
NYSE:RMD
25.80M
N/A6.9%N/A
-621.00K
N/AN/AN/A
IQVIA Holdings Inc.

IQVIA Holdings Inc. Fair Value Envelope

IQV · NYSE

Our analysis suggests that IQV has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $182.05, this represents a potential HIDDEN relative to our calculated worth for IQVIA Holdings Inc..

Intrinsic Value
Current Price: $182.05